ArticleJournal of biological engineering2026
An innovative cholesteric liquid crystal biosensor enabling high-contrast colorimetric detection and haze-based quantitation.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundA cholesteric liquid crystal (CLC) system comprising the calamitic LC 8CB (4-octyl-4’-cyanobiphenyl) doped with the chiral agent R5011 was applied as a biosensing medium.
resultsBy exploiting the pronounced light-scattering behavior at the smectic-to-chiral nematic transition temperature of 26.5 °C of the vertically aligned CLC, a distinct red–green (signal–background) color contrast was observed in the optical texture of the CLC in the presence of the protein standard bovine serum albumin (BSA) or the cancer biomarker CA125, with the red color intensity correlated positively with the concentration of the biological analyte. The high-contrast signal–background color scheme of the 8CB/R5011 CLC was confirmed through theoretical calculations to simulate the interference spectra and the corresponding color observed under a polarizing optical microscope. The simulation results also indicate that the collective tilt angle of the CLC increased in the presence of biomolecules, suggesting that the alignment of CLC was disrupted and light scattering was enhanced. By incorporating haze measurements as the quantitative approach for the CLC-based biosensor, a strong correlation between the mean haze value and the analyte concentration was demonstrated. The limit of detection (LOD) achieved through haze analysis was 1.23 × 10⁻¹² g·mL⁻1 for BSA and 3.85 × 10⁻¹⁰ g·mL⁻1 for CA125, which were substantially lower than those obtained via conventional image analysis (2.21 × 10⁻¹¹-g·mL⁻1 BSA and 1.43 × 10⁻⁹-g·mL⁻1 CA125). In a proof-of-concept demonstration with CA125-spiked human serum as the analyte, the LOD remained unaffected by interferents present in human serum.
conclusionsThe CLC-based biosensing technology combined with haze-based quantitation offers a label-free, highly sensitive, rapid response, cost-effective, and versatile platform for detecting biological analytes, manifesting significant potential for applications in early disease diagnosis and biomedical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.